{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:31:49Z","timestamp":1780090309772,"version":"3.54.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-15-00313"],"award-info":[{"award-number":["22-15-00313"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.arcmed.2025.103307","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:46:30Z","timestamp":1758710790000},"page":"103307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacogenetic Drug Administration and Community Health: A Cross-Sectional Telecommunication-Based Study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-0730","authenticated-orcid":false,"given":"Nina D.","family":"Anfinogenova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim A.","family":"Stepanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina D.","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazary P.","family":"Chesalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V.","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey N.","family":"Repin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2025.103307_bib0001","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jech-2020-214238","article-title":"Medication adherence in community-dwelling older people exposed to chronic polypharmacy","volume":"75","author":"Franchi","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.arcmed.2025.103307_bib0002","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"Bellosta","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2025.103307_bib0003","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1517\/14740338.2014.947260","article-title":"Adherence to therapy and adverse drug reactions: is there a link?","volume":"13","author":"Leporini","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.arcmed.2025.103307_bib0004","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.3390\/jcm13154289","article-title":"Clinical Significance and Patterns of Potential Drug-Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors","volume":"13","author":"Anfinogenova","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0005","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.3390\/jcm12155061","article-title":"Prescribed Versus Taken Polypharmacy and Drug-Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study","volume":"12","author":"Anfinogenova","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0006","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/ph14050487","article-title":"The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions","volume":"14","author":"Hahn","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0007","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1097\/MS9.0000000000001744","article-title":"Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease","volume":"86","author":"Shariff","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/genes16050578","article-title":"Gene-Diet Interactions in Diabetes Mellitus: Current Insights and the Potential of Personalized Nutrition","volume":"16","author":"Kapellou","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/2212798412666220620104809","article-title":"Drug-food Interactions in the Era of Molecular Big Data, Machine Intelligence, and Personalized Health","volume":"13","author":"Roy","year":"2022","journal-title":"Recent Adv Food Nutr Agric"},{"key":"10.1016\/j.arcmed.2025.103307_bib0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2025.103307_bib0011","first-page":"24","article-title":"Emerging trends and challenges of population-based cardiology","volume":"34","author":"Anfinogenova","year":"2019","journal-title":"Sib Med J"},{"key":"10.1016\/j.arcmed.2025.103307_bib0012","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1002\/cpz1.226","article-title":"PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge","volume":"1","author":"Gong","year":"2021","journal-title":"Curr Protoc"},{"key":"10.1016\/j.arcmed.2025.103307_bib0013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.arcmed.2025.103307_bib0014","unstructured":"CPIC. Clinical Pharmacogenetics Implementation Consortium (CPIC). Guidelines. https:\/\/cpicpgx.org\/guidelines (Accessed May 07, 2025)."},{"key":"10.1016\/j.arcmed.2025.103307_bib0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jcph.1336","article-title":"Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database","volume":"59","author":"Tanoshima","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.therap.2016.09.014","article-title":"Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)","volume":"72","author":"Picard","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.arcmed.2025.103307_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70009","article-title":"Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study","volume":"17","author":"Hodel","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.arcmed.2025.103307_bib0018","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1038\/s41380-024-02588-4","article-title":"Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and phenoconversion in 15,000 patients","volume":"29","author":"Patel","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.arcmed.2025.103307_bib0019","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0020","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/jpm12121972","article-title":"Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient Population","volume":"12","author":"Ashcraft","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0021","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/toxics12040260","article-title":"Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths","volume":"12","author":"Aly","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.arcmed.2025.103307_bib0022","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/s12877-024-05471-7","article-title":"Drug-gene interactions in older patients with coronary artery disease","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.arcmed.2025.103307_bib0023","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-024-45032-5","article-title":"Implementing community-engaged pharmacogenomics in Indigenous communities","volume":"15","author":"Claw","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2025.103307_bib0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s42255-024-01190-w","article-title":"Diabetes in China: epidemiology, pathophysiology and multi-omics","volume":"7","author":"Jia","year":"2025","journal-title":"Nat Metab"},{"key":"10.1016\/j.arcmed.2025.103307_bib0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-025-03558-1","article-title":"Evolution, genetic diversity, and health","volume":"31","author":"Palma-Mart\u00ednez","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0026","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/ijp.ijp_198_24","article-title":"Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour","volume":"56","author":"Chenchula","year":"2024","journal-title":"Indian J Pharmacol"},{"issue":"D1","key":"10.1016\/j.arcmed.2025.103307_bib0027","doi-asserted-by":"crossref","first-page":"D1498","DOI":"10.1093\/nar\/gkae1016","article-title":"PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important PGx genes","volume":"53","author":"Tremmel","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0028","unstructured":"Medscape. Medscape Drug Interaction Checker. https:\/\/reference.medscape.com\/drug-interaction checker (Accessed May 07, 2025)."},{"key":"10.1016\/j.arcmed.2025.103307_bib0029","unstructured":"PharmGKB. Search PharmGKB. https:\/\/www.pharmgkb.org\/(Accessed May 07, 2025)."},{"issue":"D1","key":"10.1016\/j.arcmed.2025.103307_bib0030","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0031","doi-asserted-by":"crossref","first-page":"e1773","DOI":"10.1002\/hsr2.1773","article-title":"Unveiling the sleep-cardiovascular connection: Novel perspectives and interventions-A narrative review","volume":"6","author":"Berjaoui","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.arcmed.2025.103307_bib0032","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1097\/MS9.0000000000002414","article-title":"The pulse of sleep: novel interventions in understanding the sleep-cardiovascular connection: a literature review","volume":"86","author":"Uwishema","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/postmj\/qgaf069","article-title":"AI-enhanced telemedicine for personalized antiretroviral therapy in HIV patients with neurological comorbidities: a narrative review","author":"Mugisha","year":"2025","journal-title":"Postgrad Med J"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2025.103307_bib0034","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ypmed.2014.07.028","article-title":"What is \u201ccommunity health\u201d? Examining the meaning of an evolving field in public health","volume":"67","author":"Goodman","year":"2014","journal-title":"Prev Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0035","volume":"2","year":"2020"},{"key":"10.1016\/j.arcmed.2025.103307_bib0036","unstructured":"World Health Organization. World Health Organization Data 2023. Russian Federation. Health data overview for the Russian Federation. https:\/\/data.who.int\/countries\/643 (Accessed June 23, 2025)."},{"key":"10.1016\/j.arcmed.2025.103307_bib0037","doi-asserted-by":"crossref","DOI":"10.2196\/58362","article-title":"Examining Individuals' Use of the Internet for Health Care Activities Over Time: Results from the US National Health Interview Survey","volume":"12","author":"Junkins","year":"2025","journal-title":"JMIR Hum Factors"},{"key":"10.1016\/j.arcmed.2025.103307_bib0038","doi-asserted-by":"crossref","DOI":"10.2196\/53320","article-title":"Ever Use of Telehealth in Nebraska by March 2021: Cross-Sectional Analysis","volume":"26","author":"Smith","year":"2024","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0039","doi-asserted-by":"crossref","DOI":"10.2196\/11931","article-title":"Profiles of a Health Information-Seeking Population and the Current Digital Divide: Cross-Sectional Analysis of the 2015-2016 California Health Interview Survey","volume":"21","author":"Din","year":"2019","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0040","first-page":"1850","article-title":"Sample 1 was Scand","volume":"33","author":"Nuzzo","year":"2023","journal-title":"J Med Sci Sports"},{"key":"10.1016\/j.arcmed.2025.103307_bib0041","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12874-024-02163-z","article-title":"Barriers and facilitators for recruiting and retaining male participants into longitudinal health research: a systematic review","volume":"24","author":"Borg","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0042","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.2196\/jmir.6668","article-title":"Gender-Specific Determinants and Patterns of Online Health Information Seeking: Results From a Representative German Health Survey","volume":"19","author":"Baumann","year":"2017","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0043","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijmedinf.2017.12.019","article-title":"Research on gender differences in online health communities","volume":"111","author":"Liu","year":"2018","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.arcmed.2025.103307_bib0044","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clnesp.2025.03.015","article-title":"A pilot study on traditional vs. digital self-administered questionnaire completion in the International Weight Control Registry","volume":"67","author":"Poulimeneas","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.arcmed.2025.103307_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/qjmed\/hcaf022","article-title":"Global Burden of Cardiovascular Diseases and its Risk Factors, 1990\u20132021: A Systematic Analysis for the Global Burden of Disease Study 2021","author":"Tan","year":"2025","journal-title":"QJM"},{"key":"10.1016\/j.arcmed.2025.103307_bib0046","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2022.11.001","article-title":"Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990\u20132021","volume":"80","author":"Lindstrom","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0047","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (Accessed June 23, 2025)."},{"key":"10.1016\/j.arcmed.2025.103307_bib0048","article-title":"Sirolimus potentiated angioedema: A case report and review of the literature","volume":"19","author":"Beaini","year":"2024","journal-title":"Open Med (Wars)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JRS-230006","article-title":"Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension","volume":"35","author":"Sychev","year":"2024","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1515\/dmpt-2023-0008","article-title":"Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients","volume":"38","author":"Sychev","year":"2023","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0051","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/dmpt-2022-0115","article-title":"CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study","volume":"38","author":"Sinitsina","year":"2022","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0052","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.3390\/ijms20215304","article-title":"Pathophysiology of Calcium Mediated Ventricular Arrhythmias and Novel Therapeutic Options with Focus on Gene Therapy","volume":"20","author":"Paar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2025.103307_bib0053","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10741-017-9647-y","article-title":"Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure","volume":"23","author":"Anfinogenova","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.arcmed.2025.103307_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70727","article-title":"Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review","volume":"8","author":"Mugisha","year":"2025","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.arcmed.2025.103307_bib0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics16081079","article-title":"A Pharmacogenetic Panel-Based Prediction of the Clinical Outcomes in Elderly Patients with Coronary Artery Disease","volume":"16","author":"Dong","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arcmed.2025.103307_bib0056","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2714","article-title":"Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics","volume":"113","author":"Thompson","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0057","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.2337\/dci23-0035","article-title":"Diabetes and Multiple Long-term Conditions: A Review of Our Current Global Health Challenge","volume":"46","author":"Khunti","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arcmed.2025.103307_bib0058","doi-asserted-by":"crossref","first-page":"afac285","DOI":"10.1093\/ageing\/afac285","volume":"51","author":"Masoli","year":"2022","journal-title":"Genomics and multimorbidity. Age Ageing."},{"key":"10.1016\/j.arcmed.2025.103307_bib0059","first-page":"967","article-title":"Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database","volume":"15","author":"Wittwer","year":"2022","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0060","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40264-025-01522-z","article-title":"Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data","volume":"48","author":"Wittwer","year":"2025","journal-title":"Drug Saf"},{"key":"10.1016\/j.arcmed.2025.103307_bib0061","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/jpm10030078","article-title":"Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing","volume":"10","author":"Vermehren","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0062","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-pharmtox-061724-080935","article-title":"Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation","volume":"65","author":"Mosch","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0063","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12864-025-11310-9","article-title":"Frequencies of CYP2C9 polymorphisms in a Syrian cohort","volume":"26","author":"Aldiban","year":"2025","journal-title":"BMC Genomics"},{"key":"10.1016\/j.arcmed.2025.103307_bib0064","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41397-025-00366-1","article-title":"A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study)","volume":"25","author":"Ng","year":"2025","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2025.103307_bib0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A Review of the Important Role of CYP2D6 in Pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.arcmed.2025.103307_bib0066","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1172\/JCI70430","article-title":"P-glycoprotein ABCB1: a major player in drug handling by mammals","volume":"123","author":"Borst","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcmed.2025.103307_bib0067","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.arcmed.2008.06.008","article-title":"ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India","volume":"39","author":"Singh","year":"2008","journal-title":"Arch Med Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176907","article-title":"Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases","volume":"981","author":"Agostini","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0069","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1093\/ajhp\/zxae294","article-title":"Implementation of HLA-related genotype-guided prescribing in Singapore","volume":"82","author":"Chua","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.arcmed.2025.103307_bib0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpt.3458","article-title":"Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data","volume":"117","author":"Litonius","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0071","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cpt.1489","article-title":"Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing","volume":"106","author":"van der Wouden","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0072","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70139","article-title":"Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review","volume":"7","author":"Inshutiyimana","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.arcmed.2025.103307_bib0073","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-pharmtox-030920-025745","article-title":"Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings","volume":"61","author":"Chang","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0074","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/jpm13030410","article-title":"Expanding Family Health History to Include Family Medication History","volume":"13","author":"Haga","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ehjcvp\/pvac005","article-title":"Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.arcmed.2025.103307_bib0076","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1007\/s11606-019-05531-4","article-title":"Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool","volume":"35","author":"Ramirez","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0077","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11096-021-01346-8","article-title":"Determination of potential drug-drug interactions in prescription orders dispensed in a community pharmacy setting using Micromedex\u00ae and Lexicomp\u00ae: a retrospective observational study","volume":"44","author":"Abbas","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.arcmed.2025.103307_bib0078","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jcpt.12508","article-title":"Clinical decision support systems differ in their ability to identify clinically relevant drug interactions of immunosuppressants in kidney transplant patients","volume":"42","author":"Amkreutz","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.946351","article-title":"Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases","volume":"13","author":"Hecker","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/2279-042X.192461","article-title":"A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness","volume":"5","author":"Kheshti","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"10.1016\/j.arcmed.2025.103307_bib0081","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1200\/JOP.18.00086","article-title":"Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics","volume":"14","author":"Marcath","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.arcmed.2025.103307_bib0082","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-017-2232-4","article-title":"Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study","volume":"73","author":"Muhi\u010d","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0083","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00228-022-03370-7","article-title":"COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir\/ritonavir is co-prescribed","volume":"78","author":"Yalcin","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0084","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s40520-025-03025-4","article-title":"Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase\u00ae","volume":"37","author":"Crescioli","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3","volume":"14","author":"O\u2019Mahony","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0086","first-page":"2052","article-title":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.arcmed.2025.103307_bib0087","article-title":"Interventions to improve the appropriate use of polypharmacy for older people","volume":"9","author":"Rankin","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcmed.2025.103307_bib0088","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40520-022-02094-z","article-title":"Italian guidelines on management of persons with multimorbidity and polypharmacy","volume":"34","author":"Onder","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0089","series-title":"Multimorbidity: Assessment, Prioritisation and Management of Care for People with Commonly Occurring Multimorbidity","year":"2016"},{"key":"10.1016\/j.arcmed.2025.103307_bib0090","article-title":"Exploring potential drug-drug interactions in discharge prescriptions: ChatGPT's effectiveness in assessing those interactions","volume":"17","author":"Thapa","year":"2025","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.arcmed.2025.103307_bib0091","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40266-019-00683-8","article-title":"Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients","volume":"36","author":"Scott","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.arcmed.2025.103307_bib0092","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/jgs.19474","article-title":"Development and Implementation of a Pharmacist-Led Aspirin Deprescribing Algorithm in Older Adults","volume":"733","author":"Sano","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.arcmed.2025.103307_bib0093","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.amjmed.2024.01.015","article-title":"Prevalence of Guideline-Discordant Aspirin Use and Associated Adverse Events in Patients on Warfarin for Mechanical Valve Replacement","volume":"137","author":"Haymart","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.arcmed.2025.103307_bib0094","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2215\/CJN.0000000619","article-title":"Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease","volume":"20","author":"Kim","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.arcmed.2025.103307_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102559","article-title":"Recommendations and quality of multimorbidity guidelines: A systematic review","volume":"102","author":"Wang","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.arcmed.2025.103307_bib0096","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/cpt.2754","article-title":"Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review","volume":"112","author":"Morris","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2025.103307_bib0097","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/tpj.2017.21","article-title":"Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?","volume":"17","author":"Verbelen","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2025.103307_bib0098","doi-asserted-by":"crossref","DOI":"10.2174\/011573403X334668241227074314","article-title":"Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review","volume":"21","author":"Kayani","year":"2025","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.arcmed.2025.103307_bib0099","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1186\/s12913-020-05920-0","article-title":"Comparison of self-report and administrative data sources to capture health care resource use in people with chronic obstructive pulmonary disease following pulmonary rehabilitation","volume":"20","author":"Grimwood","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.arcmed.2025.103307_bib0100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jamia\/ocz226","article-title":"Design and analytic considerations for using patient-reported health data in pragmatic clinical trials: report from an NIH Collaboratory roundtable","volume":"27","author":"Rockhold","year":"2020","journal-title":"J Am Med Inform Assoc"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T01:30:55Z","timestamp":1776562255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440925001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0188440925001274"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103307","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic Drug Administration and Community Health: A Cross-Sectional Telecommunication-Based Study","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103307"}}